The Journal of thoracic and cardiovascular surgery
-
J. Thorac. Cardiovasc. Surg. · May 1986
Randomized Controlled Trial Clinical TrialNifedipine as an adjunct to St. Thomas' Hospital cardioplegia. A double-blind, placebo-controlled, randomized clinical trial.
The cardioprotective effect of the addition of the slow calcium-channel blocker nifedipine to cardioplegic solution was tested in two double-blind placebo controlled randomized studies. The first study included 24 patients undergoing aortic-coronary bypass grafting, and the second included 24 patients undergoing aortic valve replacement. Nifedipine at a dose of 200 micrograms/L or placebo was added to St. ⋯ In conclusion, ischemia-induced degradation of nucleotides as it occurs when myocardial cooling is inadequate can be prevented by the addition of nifedipine to the St. Thomas' Hospital cardioplegic solution. This effect, however, is not associated with an improved clinical outcome.
-
J. Thorac. Cardiovasc. Surg. · May 1986
Case ReportsLong-term results after Fontan procedure and its modifications.
The Fontan procedure is an effective method of treatment for patients with tricuspid atresia, univentricular heart, and other complex lesions. Modifications of the Fontan procedure have been developed to treat various anatomic malformations. From 1975 to 1984, 31 patients (17 male and 14 female) have undergone 35 Fontan operations. ⋯ The hemodynamic ventricular parameters were within the normal range. We conclude that in patients with tricuspid atresia, univentricular heart, and other complex cardiac lesions, inactivating the right ventricular pump function by means of the Fontan procedure does not adversely affect the systemic ventricle. Although the response to exercise was abnormal, the clinical condition of these patients was good to excellent.
-
J. Thorac. Cardiovasc. Surg. · Mar 1986
Randomized Controlled Trial Clinical TrialA prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations.
A randomized, double-blind study was designed to evaluate the therapeutic effect and safety of prostacyclin (epoprostenol) in patients undergoing cardiopulmonary bypass. One hundred patients having isolated coronary bypass grafting received 300 units/kg of heparin and then either prostacyclin (12.5 ng/kg/min from heparinization until cardiopulmonary bypass, 25 ng/kg/min during bypass) or buffer/diluent in a similar manner. Standardized anesthetic, perfusion, and surgical techniques were used. ⋯ Prostacyclin may provide clinical benefits in patients undergoing cardiopulmonary bypass when there are contraindications to or other difficulties with blood transfusion. With prostacyclin, reduced heparin dose is possible and therefore reduced protamine requirement would offer a potential benefit of less cardiovascular depression immediately after bypass. However, the advantages offered by prostacyclin are not sufficient to recommend its routine use during cardiopulmonary bypass.
-
J. Thorac. Cardiovasc. Surg. · Mar 1986
Retained intracardiac air. Transesophageal echocardiography for definition of incidence and monitoring removal by improved techniques.
Retained intracardiac air is a continuing hazard for cardiopulmonary bypass. M-mode transesophageal echocardiography of the left atrium, left ventricle, and aorta is a highly sensitive method for detecting retained intracardiac air bubbles. In 15 patients having valve operations and 18 having coronary bypass, M-mode transesophageal echocardiography was used to record air bubbles during and for 15 minutes after bypass. ⋯ There are three essential elements of air removal: First is mobilization of the air; positive chamber filling, stretching of the atrial wall, and ballottement are critical. Second is removal of mobilized air; continuous ascending aorta-venous shunting and nonsuction venting of the left atrium are very important. Third is proof of elimination of air before cardiopulmonary bypass is terminated; transesophageal echocardiography is vital for this.